Search

everythinglearnresearchcommunity

for

Search:↓

Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

Cedrol may be an effective treatment for colorectal cancer.

GI197111X is best dissolved in Capmul MCM for trials.

A specific gene variant is linked to a higher risk of hair loss from chemotherapy in breast cancer patients.

Imuvert can prevent some chemotherapy-induced hair loss.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.

Tofacitinib helped a woman regrow hair with no major side effects.

Photodynamic therapy improved skin issues from sorafenib when other treatments failed.

Some existing medicines show promise as safe treatments to protect against the side effects of radiation therapy.

Tofacitinib treatment is used for teenagers with alopecia areata.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Cucurbita maxima seed extract shows promise for breast cancer treatment.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.